CD8A and neoplasm: Extending to solid cancers, M3258 inhibited tumor growth and reprogrammed the immune microenvironment of triple-negative and inflammatory breast cancer (TNBC/IBC), where it suppressed M2 macrophage growth, enhanced CD8+ T-cell infiltration, and reduced pro-inflammatory signatures (70).